Whatever Cambridge, MA-based Millennium learned over the past two years it's been collaborating with Presage Biosciences, the experience must have been rewarding. The Takeda sub has followed up with an expanded pact to use the Seattle-based company, a brainchild of Jim Olson's at the Hutch, to explore the potential of more cancer drug combinations. Presage's technology is designed to identify the most promising combination therapies, a big field in oncology these days. Presage gets an unspecified package including an upfront and milestones, but the exact terms of being kept under wraps--just like their first deal. Release